Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $104.00

Prestige Consumer Healthcare (NYSE:PBH - Free Report) had its price target raised by DA Davidson from $95.00 to $104.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on PBH. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Friday, January 24th. Sidoti lowered Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price for the company. in a research note on Monday, December 9th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $92.50.

Prestige Consumer Healthcare Stock Down 1.1 %

NYSE:PBH traded down $0.94 during mid-day trading on Friday, reaching $86.25. The stock had a trading volume of 226,195 shares, compared to its average volume of 314,727. The business's 50 day moving average is $79.28 and its 200 day moving average is $75.63. Prestige Consumer Healthcare has a fifty-two week low of $62.35 and a fifty-two week high of $88.36. The stock has a market cap of $4.26 billion, a P/E ratio of 20.20, a PEG ratio of 2.43 and a beta of 0.50. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, sell-side analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in Prestige Consumer Healthcare by 3.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock worth $19,630,000 after buying an additional 8,533 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock worth $95,678,000 after buying an additional 50,961 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 12.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock valued at $708,000 after acquiring an additional 1,120 shares during the last quarter. Avior Wealth Management LLC raised its position in shares of Prestige Consumer Healthcare by 1,570.7% during the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock valued at $668,000 after acquiring an additional 8,042 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after acquiring an additional 71,730 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.